Navigation Links
Synthetech Reports First Quarter Fiscal 2010 Results
Date:8/6/2009

===== =====

Commenting on the financial results, Dr. Gregory Hahn, President and CEO, stated, "It is a great start for fiscal year 2010. First quarter revenues of $4.7 million, operating profit of 22% and net income of $969,000 further exemplify the benefits of our actions aimed at expanding markets, improving production efficiencies, and reducing costs. We remain guardedly optimistic about overall performance for the balance of fiscal year 2010 based on a reasonable $4.6 million order backlog, a robust project pipeline providing us with additional market opportunities, and better than expected strength in our biopharmaceutical customer base. In addition, the full benefit of our cost reduction plan implemented in the first quarter begins in the second quarter."

Management anticipates that Synthetech's revenue will continue to be volatile from period to period. Variability in Synthetech's level of revenue is based primarily on its participation in large-scale customer projects and the timing of shipments arising from these projects. Synthetech operates in a challenging business environment, characterized by the unpredictable dynamics and life cycle of pharmaceutical projects, which can lead to rapid fluctuations in the mix of projects and revenues. As the uncertainties inherent in drug development projects remain outside of Synthetech's control, it is difficult to predict the progress, timing and revenue potential of these projects.

About Synthetech

Synthetech, Inc., based in Albany, Oregon, is a fine chemicals company specializing in organic synthesis, biocatalysis and chiral technologies. We develop and manufacture amino acid derivatives, specialty amino acids, peptide fragments and proprietary custom chiral intermediates and specialty resins, primarily for the pharmaceutical industry. Synthetech produces advanced pharmaceutical i
'/>"/>

SOURCE Synthetech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Synthetech Earns National Recognition for Performance Improvement Program
2. Synthetech Announces Fiscal 2008 Results
3. Synthetech Announces New Director of Manufacturing
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. QMed, Inc. Reports July Medicare SNP Enrollments
6. Phlo Affiliate Reports Expanded Coverage to Oregon Border
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
9. Carrington Reports Second Quarter 2007 Results
10. Avitar Reports Third Quarter Financial Results for Fiscal 2007
11. Response Genetics Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... ON , Aug. 22, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... six month periods ended June 30, 2014.  Biorem,s complete 2014 second quarter ... Financial Summary:Three-months ended June 30, , Six-months ended ... , 2014 , 2013 , 2014 ... , 4,433 , 9,195 Gross profit , 56 ...
(Date:8/22/2014)... Ophthalmic drug delivery technologies or ... endeavors as the anatomy, physiology and biochemistry of ... foreign substances. Ocular drug delivery technologies provide several ... minimal use of needles; also it enables high ... specific targeting within the ocular globe. On the ...
(Date:8/22/2014)... 2014 Nerium International, the go-to, ... the spotlight again. Nerium will showcase its signature ... Body Contouring Cream to Hollywood’s elite at the ... the 66th Primetime Emmy® Awards. , Developed from ... clinical trials show that NeriumAD night cream dramatically ...
(Date:8/21/2014)... at the Institute for Molecular Medicine Finland (FIMM), ... developed a novel "man and machine" decision support ... aid was described in PLOS One ... based on computer vision algorithms similar to those ... of only the diagnostically most relevant areas. Tablet ...
Breaking Biology Technology:Biorem Reports 2014 Second Quarter Results 2Biorem Reports 2014 Second Quarter Results 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 3A novel 'man and machine' decision support system makes malaria diagnostics more effective 2
... N.Y., Jan. 31 Mr. Donald Fresne, ... that the company has recently,obtained from Harvard ... cover certain technologies related to cancer therapy ... developed jointly,by scientists in the Laboratory for ...
... VCs face more competition from private ... equity and hedge ... their investments to the greentech and biotech industries in the,coming year, ... a recent survey by the U.S. audit, tax and advisory,firm KPMG ...
... 31 Schering-Plough,Corporation (NYSE: SGP ) today ... has accepted the Peg-IFN (peginterferon alfa-2b),supplemental Biologics License ... status for the adjuvant treatment of patients with,Stage ... agency,in the fall of 2007., The Priority ...
Cached Biology Technology:Venture Capitalists Bullish on Greentech and Biotech, KPMG Study Says 2Venture Capitalists Bullish on Greentech and Biotech, KPMG Study Says 3FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 2FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 3FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 4FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 5FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 6
(Date:8/21/2014)... of the water window? It consists of radiations in ... absorbed by the water in biological tissues. New theoretical ... radiations within the water window. These could be the ... image of the biological samples or to be used ... the physical mechanism needed to efficiently generate the harmonic ...
(Date:8/21/2014)... by an international standards process, will be available soon ... invited review published in the OnlineFirst version of ... official journal of the American Society for Parenteral and ... the occurrence of misconnection that can be harmful and ... used to join medical devices, components, and accessories to ...
(Date:8/21/2014)... University have developed a novel and versatile modeling strategy ... creating new materials as well as for studying polyelectrolytes, ... us to model much larger and more complex polyelectrolyte ... Nan Li, lead author of a paper on the ... of Materials Science and Engineering. "This is a big ...
Breaking Biology News(10 mins):Water window imaging opportunity 2New feeding tube connectors will improve patient safety 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2
... In 2007, researchers of the Max Planck Institute ... in exploratory behaviour in great tits. Birds with a ... (DRD4 gene) showed stronger novelty seeking and exploration behaviour ... tested and found in a lab-raised group of birds. ...
... , Some animals, it seems, are going on a ... these are reactions to rapidly rising temperatures due to ... Aviv University,s Department of Zoology, who has been measuring ... areas where climate change is most extreme. , Changes ...
... with anorexia nervosa, paradoxically, have strikingly high levels of fat ... Their findings, based on MRI imaging of the knees of ... same age, appear in the February issue of the ... that an emaciated young woman with almost no subcutaneous fat ...
Cached Biology News:Great tits: birds with character 2Animals cope with climate change at the dinner table 2Anorexics found to have excess fat-- in their bone marrow 2
... ProteinChip arrays have been developed for ... samples. A variety of ProteinChip chemical ... according to their unique biochemical properties. ... allowing side-by-side sample comparison, and the ...
The thermal printer, 120 V, is used to record fluorescence data acquired with the VersaFluor fluorometry systems. The printer includes a cable and power adaptor....
This thermal printer, 120 V, provides a permanent record of the preprogrammed method and run data for the PROTEAN IEF cell. Includes cable and power adaptor....
... iCycler thermal cycler with 384-well reaction module ... applications. It is equipped with an interchangeable, ... features algorithm temperature monitoring and control and ... sample volumes. It includes the iCycler base ...
Biology Products: